Winston & Strawn

Site Search

Professionals (208)
Capabilities (58)
Experience (147)
Insights & News (1,478)
Other Results (67)

Professionals 208 results

T. Reed Stephens

Partner

Washington, DC

+1 202-282-5795

vCard

Partner

Washington, DC

Kevin Boyle

Associate

Chicago

+1 312-558-8138

vCard

Associate

Chicago

J.R. McNair

Of Counsel

Chicago

+1 312-558-3225

vCard

Of Counsel

Chicago

View All Professionals

Capabilities 58 results

Industry

Life Sciences

Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations....Read more

Industry

Artificial Intelligence (AI)

Practice Area

Privacy: Regulated Personal Information (RPI)

Winston’s Regulated Personal Information (RPI) Practice offers seamlessly integrated counseling and litigation services to companies looking for practical and solution-oriented assistance navigating the compliance, regulatory, and private class action enforcement risks presented by the emerging patchwork of complex (and often conflicting) privacy laws in the United States and beyond....Read more

Experience 147 results

Experience

September 29, 2025

Winston Advises PJT Partners in Beyond Meat’s $1.105 Billion Exchange Offer

Winston & Strawn LLP represented PJT Partners in its role as dealer manager to Beyond Meat, Inc., a publicly traded food technology company and leading producer of plant-based meat alternatives, in connection with an exchange offer and consent solicitation for any and all of its $1.105 billion of 0% Convertible Senior Notes due 2027 for up to $202.5 million in new 7.00% Convertible Senior Secured Second Lien PIK Toggle Notes due 2030 and up to approximately 326 million shares of common stock....Read more

Experience

September 23, 2025

Denali Capital Acquisition Corp Closes Business Combination with Semnur Pharmaceuticals

Winston & Strawn LLP represented Denali Capital Acquisition Corp. (OTCQB: DNQAF), a special purpose acquisition company, in the closing of its previously announced business combination with Semnur Pharmaceuticals, Inc., a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX). ...Read more

Experience

September 22, 2025

Winston Paris advised the founders and shareholders of Bylaw, on its acquisition by Septeo

Founded in 2019 by Adrien Aboudaram and Tuan Ardouin, Bylaw has developed next-generation AI technology to automate the processing of legal and financial documents. With a team primarily dedicated to R&D, the legaltech company aims to become the leading AI reference for regulated professions....Read more

View All Experience

Insights & News 1,478 results

False Claims Act Playbook

October 30, 2025

5 Min Read

Private Equity Firm Avoids Potential False Claims Act Liability in Dismissal from Whistleblower Suit Brought by Healthcare Portfolio Company Executive

On October 15, 2025, the United States District Court for the District of Nebraska (the Court) dismissed Pharos Capital Group and its related investment funds (Pharos Capital) from a qui tam or whistleblower suit brought under the antiretaliation provision of the False Claims Act (31 U.S.C. § 3730(h)) (the FCA), against Pharos Capital and Charter Health Care Group (Charter), a portfolio company of Pharos Capital.

Life at Winston

October 21, 2025

2 Min Read

Winston For Good Heroes: Grine Lahreche Blends Local Advocacy with International Influence

Grine’s unique mix of philanthropic work connects local and international communities through compassion and a common purpose. Whether he is uniting countries around pivotal issues, mentoring children in underserved neighborhoods, or stepping into a boxing ring for charity, Grine leads by example.

Global Trade & Foreign Policy Insights

October 17, 2025

5 Min Read

Cari’s Legal Exchange: Regulatory Risks and Enforcement Realities — Part 3

Part three of Cari’s Legal Exchange explores Foreign Corrupt Practices Act (FCPA) enforcement, regulatory agency crossover, and the challenges of delisting from government sanctions lists.

View All Insights & News

Other Results 67 results

Law Glossary

What Is a Qualified Retirement Plan?

A qualified retirement plan is a retirement plan established by an employer that is designed to provide retirement income to designated employees and their beneficiaries, which meets certain IRS Code requirements in terms of both form and operation. Common plan types are 401(k) plans, pension plans, and profit-sharing plans. A qualified retirement plan may allow for both employer and employee contributions. Employers must follow procedures to ensure participants and beneficiaries are able to receive their benefits. They must also stay apprised of changes in retirement plan laws and regulations. Qualified retirement plans provide certain tax advantages to employers and tax deferral advantages to employees who are contributing. Taxes on earnings from the contributions are also deferred until the employee withdraws them from the plan....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more

Law Glossary

What Is a Biologic?

A biologic—or biologic product—is a medicine made from or by living cells, typically through a series of complex processing steps. The Public Health Service Act defines a “biological product” as “a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein (except any chemically synthesized polypeptide), or analogous product, or arsphenamine or derivative of arsphenamine (or another trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.” (42 U.S.C. § 262(i).)...Read more